Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Liabilities from Discontinued Operations: 2017

Historic Expense - Real Estate for Fortress Biotech (FBIO) over the last 2 years, with Sep 2018 value amounting to $48.6 million.

  • Fortress Biotech's Expense - Real Estate rose 18.62% to $48.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was $181.1 million, marking a year-over-year increase of 36.70%. This contributed to the annual value of $159.5 million for FY2017, which is 1403.47% up from last year.
  • Per Fortress Biotech's latest filing, its Liabilities from Discontinued Operations stood at $29.3 million for Q4 2017.
  • Over the past 5 years, Fortress Biotech's Liabilities from Discontinued Operations peaked at $29.3 million during Q4 2017, and registered a low of $29.3 million during Q4 2017.
  • In the last 3 years, Fortress Biotech's Expense - Real Estate had a median value of $41.8 million in 2017 and averaged $39.2 million.
  • Data for Fortress Biotech's Expense - Real Estate shows a peak YoY soared of 254.24% (in 2017) over the last 5 years.
  • Quarterly analysis of 3 years shows Fortress Biotech's Expense - Real Estate stood at $10.6 million in 2016, then surged by 254.24% to $37.6 million in 2017, then climbed by 18.62% to $48.6 million in 2018.
  • Its last three reported values are $48.6 million in Q3 2018, $50.5 million for Q2 2018, and $44.5 million during Q1 2018.